Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836

- **Final results expected in H2 2025**

Lyon, France – June 5, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, today announced that all participants have completed their final visit in the Phase 2a clinical booster trial (NCT06582277) evaluating OVX836, Osivax' broad-spectrum influenza A vaccine candidate. Osivax expects to announce final results from the booster trial in H2 2025.

The single-center, randomized, double-blind, Phase 2a clinical trial is being conducted at the Center for Vaccinology (CEVAC), Ghent University Hospital, in Belgium. The trial is evaluating the immunogenicity and safety of one single dose of OVX836 administered intramuscularly (IM) at either 180µg or 480µg. The study includes 117 healthy adults aged 20-64 who previously participated in Osivax' Phase 2 trials (NCT04192500 or NCT05060887), conducted 3 and 5 years ago, respectively, and who received either OVX836 (180µg, 300µg or 480µg), Influvac® Tetra, or placebo. Participants who had previously received a placebo or Influvac® Tetra now serve as controls and have received the highest dose of OVX836 (480 µg) as a primary vaccination.

"Reaching the Last Patient Last Visit in this booster trial is a significant milestone for both our team and the field of influenza vaccine development," commented **Prof. Isabel Leroux-Roels, Principal Investigator at CEVAC and Associate Professor at Ghent University.** *"This study offers the opportunity to investigate both primary and booster responses to a novel influenza vaccine over an extended time period. It has been a great experience working alongside the Osivax team, and I look forward to reviewing the data and seeing how OVX836 could contribute to improved influenza prevention strategies in the future."*

"This is an important milestone, not only for Osivax but for the broader effort to advance long-term influenza protection," said **Dr. Nicola Groth, CMO of Osivax**. *"This trial is unique in that it assesses for the first time the immune response to a booster dose administered several years after initial vaccination. The insights gained will help us understand the persistence and boostability of immune response offered by OVX836, which is essential in our goal to develop a truly broad-spectrum flu vaccine. We are thankful to the participants, investigators, and study teams whose commitment made this trial possible."*

About OVX836

OVX836 is a first-in-class influenza A vaccine candidate that targets the nucleoprotein (NP), a highly conserved internal antigen. Unlike surface antigens, the NP is much less likely to mutate, providing a broader and more universal immune response. Osivax' oligoDOM™ technology enables the design and

production of a recombinant version of the NP which self-assembles into a nanoparticle, thus triggering powerful T- and B-cell immune responses. OVX836 has been tested in 7 clinical trials with 1,400 participants so far, and has shown promising safety, immunogenicity, and efficacy read-outs.

About Osivax

Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM™, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum influenza vaccine candidate, OVX836, which is currently in Phase 2 clinical trials with over 1,400 volunteers tested and encouraging efficacy proof of concept data. Osivax's ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of Covid-19 in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide.
For further information: https://osivax.com/

Contact Osivax

Alexandre LE VERT, CEO
contact@osivax.com
+33 (0)9 70 30 13 80

For Media Inquiries

Trophic Communications
Desmond James or Anja Heuer
osivax@trophic.eu
+49 (0) 151 678 59086 or +49 (0) 151 106 199 05